Latest stories on NSRX
Nasus Pharma Announces FDA Clearance to Initiate Clinical Study of NS002 in the Treatment of Anaphylaxis
GlobeNewswire67 · bullishproduct/pr
Nasus Pharma Announces FDA Clearance to Initiate Clinical Study of NS002 in the Treatment of Anaphylaxis
StockTitan63 · neutralproduct/pr
Nasus Pharma to Participate in the H.C. Wainwright 28th Annual Global Investment Conference
GlobeNewswire56 · neutralgeneral
Nasus Pharma to Participate in the H.C. Wainwright 28th Annual Global Investment Conference
Business Insider56 · neutralproduct/pr
Nasus Pharma files $50M ordinary shares offering
The Fly24 · bearishgeneral
Nasus Pharma CFO Eyal Rubin to leave
Seeking Alpha48 · neutralgeneral
Nasus Pharma Announces Transition of Chief Financial Officer
GlobeNewswire50 · neutralgeneral
Nasus Pharma Announces Transition of Chief Financial Officer
Business Insider50 · neutralgeneral
Nasus Pharma 1H non-GAAP EPS of -$0.54
Seeking Alpha28 · bearishearnings
Nasus Pharma Boosts Cash and Equity in First-Half 2026 Filing
TipRanks56 · neutralgeneral
Nasus Pharma Reports First Half 2026 Financial Results and Provides Business Update
Business Insider56 · neutralgeneral
Nasus Pharma Reports First Half 2026 Financial Results and Provides Business Update
GlobeNewswire56 · neutralgeneral
Nasus Pharma Appoints Pharmaceutical Industry Veteran Brendan P. O'Grady as Chief Executive Officer to Lead Strategic Growth
Business Insider56 · neutralgeneral
Nasus Pharma to Participate in the Zacks Life Sciences Investor Forum | NSRX Stock News
StockTitan56 · neutralgeneral
Nasus Pharma to Host Virtual KOL Event on June 10, 2026 to Discuss NS002 for the Treatment of Anaphylaxis | NSRX Stock News
StockTitan63 · neutralproduct/pr